glucagon nasal
Selected indexed studies
- Nasal Glucagon. (Hosp Pharm, 2022) [PMID:36340624]
- Glucagon nasal powder (Baqsimi) for severe hypoglycemia. (Med Lett Drugs Ther, 2019) [PMID:31599866]
- [Nasal glucagon (Baqsimi®), new treatment for hypoglycaemic coma]. (Rev Med Liege, 2022) [PMID:36082602]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Nasal Glucagon. (2022) pubmed
- Glucagon nasal powder (Baqsimi) for severe hypoglycemia. (2019) pubmed
- [Nasal glucagon (Baqsimi®), new treatment for hypoglycaemic coma]. (2022) pubmed
- New Fast Acting Glucagon for Recovery from Hypoglycemia, a Life-Threatening Situation: Nasal Powder and Injected Stable Solutions. (2021) pubmed
- Intranasal Glucagon. (2019) pubmed
- PMID:33074627 (2020) pubmed
- Nasal Glucagon Reverses Insulin-induced Hypoglycemia With Less Rebound Hyperglycemia: Pooled Analysis of Clinical Trials. (2024) pubmed
- Population pharmacokinetics and pharmacodynamics of nasal glucagon in patients with type 1 or 2 diabetes. (2024) pubmed
- Nasal Glucagon Approved for Severe Hypoglycemia. (2019) pubmed
- Nasal glucagon as a viable alternative for treating insulin-induced hypoglycaemia in Japanese patients with type 1 or type 2 diabetes: A phase 3 randomized crossover study. (2020) pubmed